Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for BioNexus Gene Lab's Debt-to-EBITDA or its related term are showing as below:
BGLC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.4 Med: -0.06 Max: 0.81
Current: -0.08
During the past 8 years, the highest Debt-to-EBITDA Ratio of BioNexus Gene Lab was 0.81. The lowest was -0.40. And the median was -0.06.
BGLC's Debt-to-EBITDA is ranked worse than 100% of 1237
companies
in the Chemicals industry
Industry Median: 2.15
vs BGLC: -0.08
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BioNexus Gene Lab Debt-to-EBITDA Related Terms
BioNexus Gene Lab Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs VYST, QGAI, CNEY: Debt-to-EBITDA Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Debt-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
BioNexus Gene Lab (BGLC) has a Debt-to-EBITDA of -0.11 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioNexus Gene Lab. According to the industry distribution chart, BioNexus Gene Lab ranks #999999 out of 1237 companies in the Chemicals industry.
Is BioNexus Gene Lab's Debt-to-EBITDA too high?
BioNexus Gene Lab's current Debt-to-EBITDA is -0.11. Based on the distribution chart, BioNexus Gene Lab ranks #999999 out of 1237 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Debt-to-EBITDA compare to VYST and QGAI?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #999999 out of 1237 companies for Debt-to-EBITDA. This places BioNexus Gene Lab in the lower half of its industry. The industry median Debt-to-EBITDA is 2.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Chemicals company?
The median Debt-to-EBITDA among Chemicals companies is 2.15, based on 1,237 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioNexus Gene Lab. For the Chemicals industry, the median Debt-to-EBITDA is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Debt-to-EBITDA is -0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Possible Value Trap. The stock's GF Value™ is $2.15, compared to a current price of $1.41 — trading 34.4% below its estimated fair value. The current Debt-to-EBITDA is -0.11. BioNexus Gene Lab's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Debt-to-EBITDA is -0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.41 is trading 34.4% below its estimated GF Value™ of $2.15.
GuruFocus considers BioNexus Gene Lab to be Possible Value Trap.
Key valuation signals for BGLC:
Debt-to-EBITDA: -0.11
GF Value™: $2.15 vs. price of $1.41 (34.4% below fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
54GF Score
Get the complete analysis for BGLC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
